Biphasic Insulin Aspart 30 Therapy in Insulin-Naïve and Insulin-Experienced Patients with Type 2 Diabetes: Results from the Jordanian Subgroup of the A<sub>1</sub>chieve Study

作     者：Jihad Haddad Fares H. Haddad Rashad Nasser Abdel-Ellah Al-Shudifat Firas Abbas Annabi Levent Sandalci Moawia Al-Kilani 

作者机构：Prince Hamzah Hospital Amman Jordan King Hussein Medical Center Amman Jordan Italian Hospital Amman Jordan Islamic Hospital Amman Jordan Novo Nordisk Business Area Near East Istanbul Turkey Jabal Al Zayton Hospital Zarqa Jordan 

出 版 物：《Journal of Diabetes Mellitus》 (糖尿病（英文）)

年 卷 期：2014年第4卷第4期

页      面：379-387页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Biphasic Insulin Aspart 30 Jordan Type 2 Diabetes A1chieve Clinical Practice 

摘      要：Objective: To analyse the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in a Jordanian subgroup of the 24-week, non-interventional A1chieve study. Methods: A total of 509 Jordanian patients with type 2 diabetes (392 insulin-naive and 117 insulin-experienced) starting BIAsp30, alone or in combination with oral glucose-lowering drugs, were included. Safety and effectiveness outcomes were analysed over 24 weeks. Results: Patients had a mean age of 55.8 years, body mass index of 28.8 kg/m2 and diabetes duration of 9.4 years at baseline. Two serious adverse drug reactions of hypoglycaemia were reported. The proportion of patients who reported major hypoglycaemic events decreased (2.4% at baseline vs. 0.2% at Week 24, p = 0.0039). The proportion of patients reporting overall hypoglycaemia increased marginally (6.3% at baseline vs. 9.9% at Week 24, p = 0.0378), primarily attributed to a rise in minor and nocturnal hypoglycaemia reported in insulin-naive patients. From baseline to Week 24, the mean ± SD glycated haemoglobin A1c level decreased from 9.8% ± 1.4% to 7.4% ± 0.9% (p 0.001). Significant reductions after 24 weeks were also noted in the mean fasting plasma glucose, postprandial plasma glucose, lipids, systolic blood pressure and quality of life (all p 0.001), while the mean body weight increased by 1.8 ± 6.5 kg (p 0.001). Conclusion: Overall, BIAsp 30 therapy was well-tolerated and resulted in improved glycaemic control in this Jordanian subgroup over 24 weeks.